title: Recellularization of heart valve grafts by a process of adaptive remodeling.
abstract: The objective of this study was to investigate if function and durability of connective tissue grafts stems from in vivo revascularization and recellularization. Viability is important for durable valve performance, demonstrated by pulmonary autografts. A pattern of in vivo recellularization occurs in xenogeneic or allogeneic heart valves decellularized prior to implantation, dictated by the tissue matrix and functional biomechanics. Porcine or sheep heart valves were decellularized with the SynerGraft antigen reduction process (a common treatment process to remove all histologically demonstrable leaflet cells), and implanted as pulmonary (n = 11) or aortic valve (n = 9) replacements in sheep. Sheep allograft pulmonary valves (n = 4) were implanted as pulmonary valve replacements. Recellularization was evaluated histologically after 3, 4, 5, 6, and 11 months, with cell phenotypes identified using specific antibodies. SynerGraft heart valves were progressively recellularized beginning with an initial cellular infiltrate, and subsequent repopulation with mature interstitial cells. This process occurs in the conduit and then in the leaflet, and is associated with revascularization of the graft. Functional, fully developed fibrocytes, actively synthesizing type I procollagen (antibody probe) were present within 3 months. As the process matured cell density and distribution became similar to native valve leaflets with localization of smooth muscle actin positive cells at the ventricularis/spongiosa interface. After 11 months, leaflet explants had no detectable inflammatory cells, were as much as 80% repopulated, and had a distribution of smooth muscle actin positive cells similar to that of the natural leaflet. SynerGraft- treated heart valve implants are repopulated by a process typical of adaptive remodeling following implantation. This antigen reduction treatment is the first successful tissue engineering effort obtaining an implant with mature recipient cells capable of matrix protein synthesis. Normal early valve function and durability is maintained.
authors.affiliation: University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA.
authors.forename: R C
authors.initials: RC
authors.lastname: Elkins
authors.forename: S
authors.initials: S
authors.lastname: Goldstein
authors.forename: C W
authors.initials: CW
authors.lastname: Hewitt
authors.forename: S P
authors.initials: SP
authors.lastname: Walsh
authors.forename: P E
authors.initials: PE
authors.lastname: Dawson
authors.forename: J D
authors.initials: JD
authors.lastname: Ollerenshaw
authors.forename: K S
authors.initials: KS
authors.lastname: Black
authors.forename: D R
authors.initials: DR
authors.lastname: Clarke
authors.forename: M F
authors.initials: MF
authors.lastname: O'brien
mesh_terms: D000818:Animals; D024042:Collagen Type I / Q000276:immunology / Q000378:metabolism; D015925:Cryopreservation; D006082:Graft Enhancement, Immunologic; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D007150:Immunohistochemistry; D023421:Models, Animal; D011664:Pulmonary Valve / Q000166:cytology* / Q000276:immunology / Q000637:transplantation; D012756:Sheep; D013552:Swine; D013997:Time Factors; D014021:Tissue Preservation; D014183:Transplantation, Heterologous; D014184:Transplantation, Homologous
chemical_list: D024042:Collagen Type I; D000949:Histocompatibility Antigens Class II